Managing Ectopic Pregnancy

Guides ectopic pregnancy evaluation with serial β-hCG trending, discriminatory zone application, and evidence-based management algorithms per ACOG Practice Bulletin No. 193.

Why This Skill Exists

Ectopic pregnancy occurs in approximately 1–2% of all pregnancies and remains a leading cause of first-trimester maternal mortality. Ruptured ectopic pregnancy is a surgical emergency with potential for catastrophic hemorrhage. The critical clinical challenge is distinguishing ectopic from early intrauterine pregnancy (IUP) or pregnancy of unknown location (PUL) using serial β-hCG values and transvaginal ultrasound. The discriminatory zone — the β-hCG level above which an IUP should be visible on TVUS — is central to the diagnostic algorithm.

ACOG Practice Bulletin No. 193 (Tubal Ectopic Pregnancy) establishes the diagnostic criteria, methotrexate eligibility, and surgical indications. Errors in β-hCG interpretation, premature surgical intervention on a desired IUP, or delayed diagnosis of a ruptured ectopic have devastating clinical and medicolegal consequences.

Checkpoint A: Pre-Draft Intake (Mandatory)

Symptoms — abdominal/pelvic pain (unilateral vs. bilateral), vaginal bleeding, shoulder pain, dizziness, syncope? (Default: from chief complaint)
LMP and estimated gestational age — how many weeks from LMP? (Default: from history)
Initial β-hCG level — quantitative serum value and date/time drawn? (Default: from lab results)
Ultrasound findings — IUP confirmed, adnexal mass, free fluid, empty uterus? (Default: from TVUS report)
Hemodynamic stability — vital signs, orthostatic symptoms, tachycardia, hypotension? (Default: current vitals)
Risk factors — prior ectopic, prior tubal surgery, PID history, IUD in situ, IVF pregnancy, smoking? (Default: from history)
Desire for future fertility — critical for management decision (medical vs. surgical)? (Default: patient preference)
Blood type and Rh status — RhoGAM needed if Rh-negative? (Default: from prenatal or current labs)

Documents to Request

Serial β-hCG values with dates and times
Transvaginal ultrasound reports (current and prior)
CBC, type and screen, coagulation studies
CMP (renal and liver function — required for methotrexate eligibility)
Prior operative reports (tubal surgery, prior ectopic management)
Pathology reports (if prior ectopic was treated surgically)

Step 1: Apply the Diagnostic Algorithm

β-hCG and the Discriminatory Zone

The discriminatory zone is the β-hCG level above which a viable IUP should be visible on TVUS:

Discriminatory level: 3,500 IU/L (institutional range: 1,500–3,500 IU/L)
Above discriminatory zone + no IUP on TVUS = abnormal pregnancy (ectopic or failed IUP)
Below discriminatory zone + no IUP = pregnancy of unknown location (PUL) → serial β-hCG trending required

Expected β-hCG Rise in Normal IUP

Early viable IUP: β-hCG rises by at least 53% in 48 hours (minimum normal rise, per ACOG)
The traditional "doubling time of 48 hours" applies to early pregnancies (β-hCG < 10,000)
Slower rise may still be normal; < 53% rise in 48 hours is abnormal and suggests ectopic or nonviable IUP

β-hCG Decline Patterns

After completed miscarriage: β-hCG should decline by ≥ 21–35% in 48 hours
Slower than expected decline suggests retained products or ectopic
Plateau (neither rising nor falling adequately) is concerning for ectopic

Decision Matrix

| Scenario | β-hCG Trend | Ultrasound | Action | |---|---|---|---| | Normal IUP | Rising ≥ 53%/48 hrs | IUP confirmed | Routine prenatal care | | Ectopic confirmed | Any level | Adnexal mass + no IUP; or extrauterine gestational sac with yolk sac/embryo | Manage ectopic (medical or surgical) | | PUL — likely viable IUP | Rising ≥ 53%/48 hrs | Empty uterus, below discriminatory zone | Repeat β-hCG in 48–72 hrs + TVUS when above discriminatory zone | | PUL — likely nonviable | Rising < 53%/48 hrs or plateauing | Empty uterus | Ectopic vs. failing IUP; consider D&C with path or serial monitoring | | PUL — declining | Falling > 50% in 48 hrs | Empty uterus | Likely completed miscarriage; follow to β-hCG < 5 | | Ruptured ectopic | Any level | Free fluid, hemodynamic instability | Emergent surgery — do not delay |

Step 2: Methotrexate (Medical Management)

Eligibility Criteria for Methotrexate

| Criteria | Requirement | |---|---| | Hemodynamic stability | Required — unstable patients → surgery | | Ectopic mass size | ≤ 3.5 cm (per ACOG; some extend to 4 cm) | | No fetal cardiac activity on US | Required (cardiac activity = relative contraindication, higher failure rate) | | β-hCG level | < 5,000 IU/L ideal; success rate drops above 5,000 | | Patient ability to follow up | Must be able to return for serial β-hCG monitoring | | Renal function | Normal creatinine | | Hepatic function | Normal transaminases | | WBC count | > 1,500/μL | | Platelet count | > 100,000/μL | | No immunodeficiency | — | | No breastfeeding | Methotrexate is contraindicated in breastfeeding |

Methotrexate Protocols

| Protocol | Dosing | Monitoring | |---|---|---| | Single-dose | MTX 50 mg/m² IM (day 1) | β-hCG days 4 and 7; if < 15% decline between days 4–7, give second dose | | Two-dose | MTX 50 mg/m² IM days 1 and 4 | β-hCG days 4 and 7; if < 15% decline between days 4–7, give doses on days 7 and 11 | | Multi-dose | MTX 1 mg/kg IM on days 1, 3, 5, 7 alternating with leucovorin 0.1 mg/kg on days 2, 4, 6, 8 | β-hCG before each MTX dose; stop when 15% decline achieved |

Post-methotrexate monitoring:

Weekly β-hCG until < 5 IU/L
Avoid NSAIDs, folate supplements, alcohol, and intercourse until resolved
Warn about transient β-hCG rise between days 1–4 (expected, not treatment failure)
Watch for treatment failure signs: increasing pain, hemodynamic change, rising β-hCG after day 7

Step 3: Surgical Management

Indications for Surgery

Hemodynamic instability (ruptured ectopic)
Contraindication to methotrexate
Failed methotrexate (rising β-hCG after day 7 of second dose)
Patient preference
Fetal cardiac activity on ultrasound
β-hCG > 5,000 IU/L (higher failure rate with medical management)

Surgical Options

| Procedure | Description | Fertility Considerations | |---|---|---| | Salpingostomy | Linear incision over ectopic, removal of products, tube preserved | Preferred if contralateral tube is damaged or absent | | Salpingectomy | Complete removal of affected tube | Preferred if contralateral tube is healthy; lower recurrence risk |

Post-surgical:

Follow β-hCG weekly to < 5 IU/L (persistent ectopic tissue requires retreatment in 5–20% of salpingostomy cases)
RhoGAM if Rh-negative (50 mcg if < 12 weeks, 300 mcg if ≥ 12 weeks)
Pathology confirmation of ectopic tissue

Step 4: Special Situations

Heterotopic Pregnancy

Coexisting IUP + ectopic; incidence is 1:30,000 naturally but up to 1:100 with ART
Methotrexate is contraindicated (would harm the IUP)
Treatment: surgical removal of ectopic with preservation of IUP

Interstitial (Cornual) Ectopic

Located in intramural portion of the tube
Higher rupture risk with more severe hemorrhage
May present later (up to 12–16 weeks) due to myometrial distensibility
Surgical: cornual resection or cornuostomy; consider uterine artery embolization

Cesarean Scar Ectopic

Implantation within the cesarean scar niche
Increasing incidence with rising cesarean rates
Management: methotrexate, uterine artery embolization, hysteroscopic resection, or laparotomy

Checkpoint B: Post-Draft Alignment (Mandatory)

Is the β-hCG trend documented with at least two values, dates, and calculated % change?
Is the discriminatory zone applied correctly — and does the action match the scenario?
Are methotrexate eligibility criteria checked before recommending medical management?
Is Rh status addressed with RhoGAM administered or planned if Rh-negative?
Is the follow-up plan explicit — serial β-hCG schedule, return precautions, and failure criteria?

Quality Audit

[ ] Quantitative β-hCG documented with date, time, and serial values
[ ] β-hCG trend calculated (% rise or decline in 48 hours)
[ ] Discriminatory zone defined (institutional threshold stated)
[ ] TVUS findings documented (IUP present/absent, adnexal mass, free fluid)
[ ] Hemodynamic status documented
[ ] Risk factors for ectopic documented
[ ] Methotrexate eligibility criteria systematically checked (all elements)
[ ] Methotrexate protocol specified (single-dose, two-dose, or multi-dose) with dosing
[ ] Post-methotrexate monitoring schedule documented
[ ] Surgical indication documented (if operative management chosen)
[ ] Procedure type documented (salpingostomy vs. salpingectomy) with rationale
[ ] Rh status documented and RhoGAM administered/planned
[ ] Pathology confirmation of ectopic tissue documented (surgical cases)
[ ] Patient counseled on ectopic precautions (pain, bleeding, return to ED)
[ ] β-hCG follow-up schedule documented until < 5 IU/L

Guidelines

Never diagnose ectopic based on a single β-hCG — serial values and ultrasound findings are required for diagnosis (unless ultrasound shows definitive extrauterine pregnancy with cardiac activity).
The discriminatory zone is a guideline, not an absolute — multiple gestations and early IUPs may not be visible at the traditional threshold; use caution before intervening on a desired pregnancy.
A rising β-hCG does not exclude ectopic — ectopic pregnancies can show normal-appearing rises in up to 21% of cases.
Methotrexate is not risk-free — it requires reliable patient follow-up; do not administer if the patient cannot return for serial monitoring.
Ruptured ectopic is a surgical emergency — hemodynamic instability with a positive pregnancy test and free fluid mandates immediate operative intervention without waiting for β-hCG trends.
Salpingectomy is preferred when the contralateral tube is healthy — it eliminates the risk of persistent ectopic and recurrence in the same tube.
Follow β-hCG to zero after ANY ectopic management — persistent trophoblastic tissue occurs in 5–20% of salpingostomy cases and requires surveillance.
Always give RhoGAM to Rh-negative patients — ectopic pregnancy is a sensitizing event.